Abivax announces the presentation of four scientific abstracts on its obefazimod in moderately to severely active ulcerative colitis (UC), at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO), scheduled for February 21-24 in Stockholm.

The ECCO congress provides us with an excellent platform to present our new data and continue to raise awareness of obefazimod's unique mechanism of action", comments Sheldon Sloan, Abivax's Medical Director.

According to the biopharmaceutical company, data on its lead drug candidate "indicate that it exerts its anti-inflammatory activity by stabilizing the immune response in patients with ulcerative colitis".

Copyright (c) 2024 CercleFinance.com. All rights reserved.